Anti-CD80 antibodies

Details Anti-CD80 antibodies Anti-CD80 antibodies

2004-11-15

2008-01-29

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S155100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700

Reexamination Certificate

active

07323170

ABSTRACT:
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three PRIMATIZED® antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, PRIMATIZED® 7C10, PRIMATIZED® 7B6 and PRIMATIZED® 16C10. These PRIMATIZED® and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5116964 (1992-05-01), Capon
patent: 5304635 (1994-03-01), Imam et al.
patent: 5434131 (1995-07-01), Linsley
patent: 5521288 (1996-05-01), Linsley
patent: 5747034 (1998-05-01), de Boer
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5885579 (1999-03-01), Linsley
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6162432 (2000-12-01), Wallner
patent: 6709654 (2004-03-01), Anderson et al.
patent: 6893638 (2005-05-01), Anderson et al.
patent: 7192585 (2007-03-01), Anderson et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0451216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 194 276 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0682040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 92/06193 (1992-04-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/22619 (1995-08-01), None
patent: WO 96/40878 (1996-12-01), None
patent: WO 98/19706 (1998-05-01), None
Freeman et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7,”J. Exp. Med., 1991, 174(3): 625-631.
Kuntz et al., “Structure-based strategies for drug design and discovery,”Science, 1992, 257: 1078-1082.
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox,” in Merz et al. (ed.),The Protein Folding Problem and Tertiary Structure Prediction, Birithauser, Boston, MA, pp. 492-495.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotechnology, 2000, 18:34-39.
Webster II New Riverside University Dictionary, 1988, pp. 435 and 762.
Paul (ed.),Fundamental Immunology, Raven Press, 1993 p. 242.
Daikh et al., “The CD28-B6 Costimulatory Pathway and its role in Autoimmune Disease,”J. of Leukocyte Biology, 1997, 62:156-162.
Hariharan et al., “Therapeutic Activity of IDEC-114, (Anti-CD80) and Rituximab (Rituxan) in B-Cell Lymphoma,”Blood, 2001, 11 (Part 1):608a.
Razi-Wolf et al., “Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells,”Proc. Natl. Acad. Sci. U.S.A., 1992, 89(9):4210-4214.
Mehta et al., “The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis,”Cellular Immunology, 1994, 155:95-110.
Weiner et al., “Monoclonal antibody therapy of B cell lymphoma,”Expert Opin. Biol. Ther., 2004, 4:375-385.
Hathcock et al.,J. Exp. Med.180:631-640 (1994).
Gool et al.,Blood83:176-183 (1994).
Armitage, R.J., et al., Molecular and biologial characterization of a murine ligand for CD40, Nature, 1992, 357:80-82.
Azuma, M. et al., Functional Expression of B7/BB1 on Activated T Lymphocytes, J. Exp. Med., 1992, 177:845-850.
Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol., 1981, 11:195-199.
Blazar, B.R. et al., Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells, J Immunol., 1996, 157:3250-3259.
Capon, D.J., et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, 1989, 337, 525-531.
Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett., 1985, 188(1):33-36.
Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 1994, 145(3), 200-205 & 244-249.
Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 1993, 261:1328-1330.
Freeman, G.J. et al., Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice, Science, 1993, 262:907-909.
Freeman, G.J. et al., B7, A new member of the Ig Superfamily with unique expression on activated and neoplastic B cells, J of Immunol., 1989, 143:2714-2722.
Freeman, G.J. et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science, 1993, 262:909-911.
Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
Gottlieb, A. et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol., 2000, 114:840, Abstract No. 546.
Gottlieb, A. et al., Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody, J Am Acad Dermatol., 2002, 47:692-700.
Guinan, E.C. et al., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood, 1994, 84:3261-3282.
Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 1991, 636:251-265.
Hariharan et al., “In vitro and in vivo studies demonstrating the effectiveness of IDEC-114 and rituximab (Rituxan® ) in therapy of B-cell lymphoma in experimental models; Confidential Report (laboratory notebook and data binder 2552, 2646, 2665, and 2671),” Jun. 29, 2001.
Hathcock, K.S. et al., Identification of an alternative CTLA-4 ligand costimulatory for T cell activation, Science, 1993, 262:905-907.
Hollenbaugh, D., et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, The EMBO J., 1992, 11(12):4313-4321.
Kahan, B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
Karpus, W.J., et al., CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis, J. Immunol., 1989, 143:3492-3497.
Laman, J., et al., The role of gp39 (CD40 ligand) in EAE and MS, Journal of Neuroimmunology, 1994, 54(1-2):175.
Lederman, S., et al., Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), J. Exp. Med., 1992, 175:1091-1101.
Lider, O., et al., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelir basic protein, J. Immunol., 1989, 142:748-752.
Linsley, P.S. et al., The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol., 1993, 11:191-212.
Linsley, P.S. et al., T-cell antigen CD28 mediates adhesion with B cells by

Affiliated with

Also associated with

Rating

Anti-CD80 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-CD80 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD80 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963708